Sign in with your email address username.


[Correspondence] EXAMINE: targeting risk and treatment in diabetes

We read the report by Faiez Zannad and colleagues1 with great interest, especially in the context of the SAVOR-TIMI 53 study.2 Both analyses found significant cardiovascular event rates only in patients with high concentrations of N-terminal pro brain natriuretic peptide (NT-proBNP); adverse events in patients with low concentrations of NT-proBNP were negligible. This result is in accordance with previous findings,3–5 which proves that NT-proBNP is currently the best marker for cardiovascular-risk stratification in patients with diabetes.